KLK3 and metastatic neoplasm: Generally, compared with no screening, routine PSA screening is projected to reduce the 30-year average incidence of metastatic disease at diagnosis from 38.84 to 9.18–20.02 cases per 100,000 population and to lower the annual case-fatality rate from 6.14% to 2.86–3.21%.